These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2191584)

  • 1. Peripheral action of spironolactone: plethysmographic studies.
    Clement DL
    Am J Cardiol; 1990 Jun; 65(23):12K-13K. PubMed ID: 2191584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of spironolactone on systemic blood pressure, limb blood flow and response to sympathetic stimulation in hypertensive patients.
    Clement DL
    Eur J Clin Pharmacol; 1982; 21(4):263-7. PubMed ID: 7035184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of isradipine on peripheral hemodynamic reflex responses in mild-to-moderate essential hypertension.
    Duprez D; De Backer T; De Pue N; Hermans L; De Buyzere M; Clement DL
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):194S-196S. PubMed ID: 1827020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral vascular changes and ambulatory blood pressure profiles.
    Duprez D; De Buyzere M; De Sutter J; De Backer T; Clement DL
    Am J Hypertens; 1993 Dec; 6(12):1033-9. PubMed ID: 8136094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients.
    Davies J; Gavin A; Band M; Morris A; Struthers A
    Br J Clin Pharmacol; 2005 May; 59(5):520-3. PubMed ID: 15842549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spironolactone versus nifedipine in essential hypertension.
    Henry M; Wehrlen M; Pelletier B; Capron MH
    Am J Cardiol; 1990 Jun; 65(23):36K-38K. PubMed ID: 2191588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACE inhibition with spirapril improves diastolic function at rest independent of vasodilation during treatment with spirapril in mild to moderate hypertension.
    Petersen JR; Drabaek H; Gleerup G; Mehlsen J; Petersen LJ; Winther K
    Angiology; 1996 Mar; 47(3):233-40. PubMed ID: 8638865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.
    Václavík J; Sedlák R; Plachy M; Navrátil K; Plásek J; Jarkovsky J; Václavík T; Husár R; Kociánová E; Táborsky M
    Hypertension; 2011 Jun; 57(6):1069-75. PubMed ID: 21536989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral action of spironolactone: improvement in arterial elasticity.
    Lagrue G; Ansquer JC; Meyer-Heine A
    Am J Cardiol; 1990 Jun; 65(23):9K-11K; discussion 3K. PubMed ID: 1972314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension.
    Vaclavik J; Sedlak R; Jarkovsky J; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Mar; 157(1):50-5. PubMed ID: 23128822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind comparison of spironolactone and hydrochlorothiazide in hypertensive patients treated with metoprolol.
    Lavenius B; Hansson L
    Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):291-5. PubMed ID: 7049966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic effects of metoprolol and methyldopa on calf blood flow in intermittent claudication.
    Lepäntalo M
    Br J Clin Pharmacol; 1984 Jul; 18(1):90-3. PubMed ID: 6378235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial.
    Oxlund CS; Henriksen JE; Tarnow L; Schousboe K; Gram J; Jacobsen IA
    J Hypertens; 2013 Oct; 31(10):2094-102. PubMed ID: 24107738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials.
    Liu L; Xu B; Ju Y
    Clin Exp Hypertens; 2017; 39(3):257-263. PubMed ID: 28448185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
    White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA
    Hypertension; 2003 May; 41(5):1021-6. PubMed ID: 12682082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spironolactone for hypertension.
    Batterink J; Stabler SN; Tejani AM; Fowkes CT
    Cochrane Database Syst Rev; 2010 Aug; (8):CD008169. PubMed ID: 20687095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of spironolactone therapy in patients with true resistant hypertension.
    de Souza F; Muxfeldt E; Fiszman R; Salles G
    Hypertension; 2010 Jan; 55(1):147-52. PubMed ID: 19858405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of chlorthalidone and spironolactone in low--renin essential hypertension.
    Kreeft JH; Larochelle P; Ogilvie RI
    Can Med Assoc J; 1983 Jan; 128(1):31-4. PubMed ID: 6336600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of spironolactone on digital vascular reactivity in essential hypertension.
    Mendlowitz M; Naftchi NE; Gitlow SE; Wolf RL
    Am Heart J; 1968 Dec; 76(6):795-8. PubMed ID: 5721837
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of indoramin on finger circulation in patients with Raynaud disease.
    Clement DL; Duprez D; De Pue N
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S84-7. PubMed ID: 2423806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.